open access

Vol 13, No 3 (2018)
Heart failure
Published online: 2018-07-15
Get Citation

Heart failure with reduced ejection fraction — what do we know from QUALIFY registry?

Małgorzata Lelonek
DOI: 10.5603/FC.2018.0050
·
Folia Cardiologica 2018;13(3):259-262.

open access

Vol 13, No 3 (2018)
Heart failure
Published online: 2018-07-15

Abstract

In Poland epidemiological data of heart failure are serious. QUALIFY registry gives important data about outpatients with
heart failure with reduced ejection fraction (HFrEF) and their pharmacotherapy and prognosis. The results of QUALIFY
point the need of therapy improvement in HFrEF in ambulatory care. We still do not implement the optimal recommended therapy in HFrEF.

Abstract

In Poland epidemiological data of heart failure are serious. QUALIFY registry gives important data about outpatients with
heart failure with reduced ejection fraction (HFrEF) and their pharmacotherapy and prognosis. The results of QUALIFY
point the need of therapy improvement in HFrEF in ambulatory care. We still do not implement the optimal recommended therapy in HFrEF.

Get Citation

Keywords

HFrEF, guidelines adherence, prognosis

About this article
Title

Heart failure with reduced ejection fraction — what do we know from QUALIFY registry?

Journal

Folia Cardiologica

Issue

Vol 13, No 3 (2018)

Pages

259-262

Published online

2018-07-15

DOI

10.5603/FC.2018.0050

Bibliographic record

Folia Cardiologica 2018;13(3):259-262.

Keywords

HFrEF
guidelines adherence
prognosis

Authors

Małgorzata Lelonek

References (12)
  1. OECD Health Statistics 2017. http://www.oecd.org /els/health-systems/health-data.htm (2018-05-23).
  2. Gierczyński J, Wróblewski T, Gilewski M. Priorytety zdrowotne w kontekście demograficznego i gospodarczego rozwoju Polski. Wnioski i rekomendacje na przykładzie niewydolności serca. Raport Warsaw Enterprise Institute, Warszawa 2018.
  3. Niewydolność serca w Polsce — raport 2016. Materiały informacyjne Sekcji Niewydolności Serca PTK. http://www.niewydolnosc- serca.pl/barometr.pdf (2018-05-23).
  4. Komajda M, Anker SD, Cowie MR, et al. QUALIFY Investigators. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016; 18(5): 514–522.
  5. Opolski G, Ozierański K, Lelonek M, et al. Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey. Pol Arch Intern Med. 2017; 127(10): 657–665.
  6. Komajda M, Cowie MR, Tavazzi L, et al. QUALIFY Investigators. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017; 19(11): 1414–1423.
  7. Zannad F, McMurray JJV, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1): 11–21.
  8. Krum H, Shi H, Pitt B, et al. EMPHASIS-HF Study Group. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail. 2013; 6(4): 711–718.
  9. Rogers JK, McMurray JJV, Pocock SJ, et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012; 126(19): 2317–2323.
  10. Ponikowski P, Voors A, Anker S, et al. Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiologia Pol. 2016; 74(10): 1037–1147.
  11. Lelonek M. The need to apply the best therapy in heart failure — the era after PARADIGM-HF. Archives of Medical Science. 2017; 5: 1244–1248.
  12. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl